Personalized weight-loss care benefits breast cancer survivors, JHU-led study finds

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.

Scientific advances have produced therapies that allow some people with metastatic breast cancer to live longer and better. We want that progress to continue, and we will continue to fight for the right research necessary to achieve it.

September 18, 2026

Vol.52 No.34

By Frances M. Visco and Michelle Tregear

Clinical Roundup

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

September 18, 2026

Vol.52 No.34

Drugs & Targets

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

FDA approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

September 18, 2026

Vol.52 No.34

In Brief

Alastair Thompson to lead IU’s breast cancer center

Alastair Thompson was named director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center’s Vera Bradley Foundation Center for Breast Cancer Research.

August 07, 2026

Vol.52 No.31

Clinical Roundup

BRCA-negative patients may still be high-risk for breast cancer, study finds

Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by investigators at Cedars-Sinai Medical Center, the University of Toronto, and the University of Sydney.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Researchers at the University of Kansas Cancer Center, Emory University School of Medicine, and the international Southwest Oncology Group Cancer Research Network have identified a blood biomarker that may help thousands of women with hormone receptor-positive breast cancer avoid unnecessary chemotherapy.

August 07, 2026

Vol.52 No.31

Personalized weight-loss care benefits breast cancer survivors, JHU-led study finds

YOU MAY BE INTERESTED IN

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Alastair Thompson to lead IU’s breast cancer center

BRCA-negative patients may still be high-risk for breast cancer, study finds

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Renew today!

Subscriber content

Never miss an issue!

Login

Personalized weight-loss care benefits breast cancer survivors, JHU-led study finds

YOU MAY BE INTERESTED IN

Scientific progress can’t help people if they can’t access careThis is a policy problem. And it is one we can change.

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Alastair Thompson to lead IU’s breast cancer center

BRCA-negative patients may still be high-risk for breast cancer, study finds

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Never miss an issue!

Login

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.